Reviews Follitropin Beta Injection


No reviews yet.

Follistim AQ Cartridge Drug Description
Follistim® AQ Cartridge
(follitropin beta) Injection
FOR SUBCUTANEOUS USE ONLY
DRUG DESCRIPTION



What are the possible side effects of follicle stimulating hormone (Follistim, Follistim AQ, Gonal-F, Gonal-f RFF, Gonal-f RFF Pen)?

Stop using follicle stimulating hormone and seek emergency medical attention or notify your doctor immediately if you experience any of the following serious side effects:

an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
pain, warmth, redness, numbness, or tingling in an arm or leg (which may indicate a blood clot);
confusion, severe...
Read All Potential Side Effects for Follistim AQ Cartridge »




Follistim® AQ Cartridge (follitropin beta injection) contains human follicle-stimulating
hormone (hFSH), a glycoprotein hormone which is manufactured by recombinant
DNA (rDNA) technology. The active drug substance, follitropin beta, has a dimeric
structure containing two glycoprotein subunits (alpha and beta). Both the 92
amino acid alpha-chain and the 111 amino acid beta-chain have complex heterogeneous
structures arising from two N-linked oligosaccharide chains. Follitropin beta
is synthesized in a Chinese hamster ovary (CHO) cell line that has been transfected
with a plasmid containing the two subunit DNA sequences encoding for hFSH. The
purification process results in a highly purified preparation with a consistent
hFSH isoform profile and high specific activity.1 The biological
activity is determined by measuring the increase in ovary weight in female rats.
The intrinsic luteinizing hormone (LH) activity in follitropin beta is less
than 1 IU per 40,000 IU FSH. The compound is considered to contain no LH activity.

The amino acid sequence and tertiary structure of follitropin beta are indistinguishable
from that of human follicle-stimulating hormone (hFSH) of urinary source. Also,
based on available data derived from physiochemical tests and bioassay, follitropin
beta and follitropin alfa, another recombinant follicle-stimulating hormone
product, are indistinguishable.
Follistim® AQ Cartridge is a ready-for-use, prefilled with solution, disposable
cartridge containing either 175 IU of follitropin beta in 0.210 mL (833 IU/mL),
350 IU in 0.420 mL (833 IU/mL), 650 IU in 0.780 mL (833 IU/mL) or 975 IU in
1.170 mL (833 IU/mL) of aqueous solution for multiple dose use, with a maximal
deliverable dose of either 150 IU, 300 IU, 600 IU or 900 IU, respectively.
Inactive ingredients in the cartridges include: benzyl alcohol, NF 10 mg/mL;
L-methionine, USP 0.5 mg/mL; polysorbate 20, NF 0.2 mg/mL; sodium citrate (dihydrate),
USP 14.7 mg/mL; sucrose, NF 50 mg/mL; and water for injection, USP. Hydrochloric
acid, NF and/or sodium hydroxide, NF are used to adjust the pH to 7.
Follistim® AQ Cartridge is for use only with the Follistim Pen®, which
features an adjustable dosing system for administering the drug in a microvolume
of solution. The Follistim Pen®with Follistim® AQ Cartridge is intended
for SUBCUTANEOUS USE ONLY. The recombinant protein in Follistim® AQ Cartridge
has been standardized for FSH in vivo bioactivity in terms of the First
International Reference Preparation for human menopausal gonadotropins (code
70/45), issued by the World Health Organization Expert Committee on Biological
Standardization (1982). Under current storage conditions, Follistim®
AQ Cartridge may contain up to 11% of oxidized follitropin beta.
In clinical trials with Follistim® (follitropin beta for injection),
serum antibodies to FSH or anti-CHO cell derived proteins were not detected
in any of the treated patients after exposure to Follistim® for up
to three cycles.
Therapeutic Class: Infertility
1 As determined by the Ph. Eur. test for FSH in vivo bioactivity
and on the basis of the molar extinction coefficient at 277 nm (ε s:mg-1cm-1)
= 1.066.Last reviewed on RxList: 2/27/2009




Follistim AQ Cartridge Drug Description
Follistim® AQ Cartridge
(follitropin beta) Injection
FOR SUBCUTANEOUS USE ONLY
DRUG DESCRIPTION



What are the possible side effects of follicle stimulating hormone (Follistim, Follistim AQ, Gonal-F, Gonal-f RFF, Gonal-f RFF Pen)?

Stop using follicle stimulating hormone and seek emergency medical attention or notify your doctor immediately if you experience any of the following serious side effects:

an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
pain, warmth, redness, numbness, or tingling in an arm or leg (which may indicate a blood clot);
confusion, severe...
Read All Potential Side Effects for Follistim AQ Cartridge »




Follistim® AQ Cartridge (follitropin beta injection) contains human follicle-stimulating
hormone (hFSH), a glycoprotein hormone which is manufactured by recombinant
DNA (rDNA) technology. The active drug substance, follitropin beta, has a dimeric
structure containing two glycoprotein subunits (alpha and beta). Both the 92
amino acid alpha-chain and the 111 amino acid beta-chain have complex heterogeneous
structures arising from two N-linked oligosaccharide chains. Follitropin beta
is synthesized in a Chinese hamster ovary (CHO) cell line that has been transfected
with a plasmid containing the two subunit DNA sequences encoding for hFSH. The
purification process results in a highly purified preparation with a consistent
hFSH isoform profile and high specific activity.1 The biological
activity is determined by measuring the increase in ovary weight in female rats.
The intrinsic luteinizing hormone (LH) activity in follitropin beta is less
than 1 IU per 40,000 IU FSH. The compound is considered to contain no LH activity.

The amino acid sequence and tertiary structure of follitropin beta are indistinguishable
from that of human follicle-stimulating hormone (hFSH) of urinary source. Also,
based on available data derived from physiochemical tests and bioassay, follitropin
beta and follitropin alfa, another recombinant follicle-stimulating hormone
product, are indistinguishable.
Follistim® AQ Cartridge is a ready-for-use, prefilled with solution, disposable
cartridge containing either 175 IU of follitropin beta in 0.210 mL (833 IU/mL),
350 IU in 0.420 mL (833 IU/mL), 650 IU in 0.780 mL (833 IU/mL) or 975 IU in
1.170 mL (833 IU/mL) of aqueous solution for multiple dose use, with a maximal
deliverable dose of either 150 IU, 300 IU, 600 IU or 900 IU, respectively.
Inactive ingredients in the cartridges include: benzyl alcohol, NF 10 mg/mL;
L-methionine, USP 0.5 mg/mL; polysorbate 20, NF 0.2 mg/mL; sodium citrate (dihydrate),
USP 14.7 mg/mL; sucrose, NF 50 mg/mL; and water for injection, USP. Hydrochloric
acid, NF and/or sodium hydroxide, NF are used to adjust the pH to 7.
Follistim® AQ Cartridge is for use only with the Follistim Pen®, which
features an adjustable dosing system for administering the drug in a microvolume
of solution. The Follistim Pen®with Follistim® AQ Cartridge is intended
for SUBCUTANEOUS USE ONLY. The recombinant protein in Follistim® AQ Cartridge
has been standardized for FSH in vivo bioactivity in terms of the First
International Reference Preparation for human menopausal gonadotropins (code
70/45), issued by the World Health Organization Expert Committee on Biological
Standardization (1982). Under current storage conditions, Follistim®
AQ Cartridge may contain up to 11% of oxidized follitropin beta.
In clinical trials with Follistim® (follitropin beta for injection),
serum antibodies to FSH or anti-CHO cell derived proteins were not detected
in any of the treated patients after exposure to Follistim® for up
to three cycles.
Therapeutic Class: Infertility
1 As determined by the Ph. Eur. test for FSH in vivo bioactivity
and on the basis of the molar extinction coefficient at 277 nm (ε s:mg-1cm-1)
= 1.066.Last reviewed on RxList: 2/27/2009




Follistim AQ Cartridge Drug Description
Follistim® AQ Cartridge
(follitropin beta) Injection
FOR SUBCUTANEOUS USE ONLY
DRUG DESCRIPTION



What are the possible side effects of follicle stimulating hormone (Follistim, Follistim AQ, Gonal-F, Gonal-f RFF, Gonal-f RFF Pen)?

Stop using follicle stimulating hormone and seek emergency medical attention or notify your doctor immediately if you experience any of the following serious side effects:

an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
pain, warmth, redness, numbness, or tingling in an arm or leg (which may indicate a blood clot);
confusion, severe...
Read All Potential Side Effects for Follistim AQ Cartridge »




Follistim® AQ Cartridge (follitropin beta injection) contains human follicle-stimulating
hormone (hFSH), a glycoprotein hormone which is manufactured by recombinant
DNA (rDNA) technology. The active drug substance, follitropin beta, has a dimeric
structure containing two glycoprotein subunits (alpha and beta). Both the 92
amino acid alpha-chain and the 111 amino acid beta-chain have complex heterogeneous
structures arising from two N-linked oligosaccharide chains. Follitropin beta
is synthesized in a Chinese hamster ovary (CHO) cell line that has been transfected
with a plasmid containing the two subunit DNA sequences encoding for hFSH. The
purification process results in a highly purified preparation with a consistent
hFSH isoform profile and high specific activity.1 The biological
activity is determined by measuring the increase in ovary weight in female rats.
The intrinsic luteinizing hormone (LH) activity in follitropin beta is less
than 1 IU per 40,000 IU FSH. The compound is considered to contain no LH activity.

The amino acid sequence and tertiary structure of follitropin beta are indistinguishable
from that of human follicle-stimulating hormone (hFSH) of urinary source. Also,
based on available data derived from physiochemical tests and bioassay, follitropin
beta and follitropin alfa, another recombinant follicle-stimulating hormone
product, are indistinguishable.
Follistim® AQ Cartridge is a ready-for-use, prefilled with solution, disposable
cartridge containing either 175 IU of follitropin beta in 0.210 mL (833 IU/mL),
350 IU in 0.420 mL (833 IU/mL), 650 IU in 0.780 mL (833 IU/mL) or 975 IU in
1.170 mL (833 IU/mL) of aqueous solution for multiple dose use, with a maximal
deliverable dose of either 150 IU, 300 IU, 600 IU or 900 IU, respectively.
Inactive ingredients in the cartridges include: benzyl alcohol, NF 10 mg/mL;
L-methionine, USP 0.5 mg/mL; polysorbate 20, NF 0.2 mg/mL; sodium citrate (dihydrate),
USP 14.7 mg/mL; sucrose, NF 50 mg/mL; and water for injection, USP. Hydrochloric
acid, NF and/or sodium hydroxide, NF are used to adjust the pH to 7.
Follistim® AQ Cartridge is for use only with the Follistim Pen®, which
features an adjustable dosing system for administering the drug in a microvolume
of solution. The Follistim Pen®with Follistim® AQ Cartridge is intended
for SUBCUTANEOUS USE ONLY. The recombinant protein in Follistim® AQ Cartridge
has been standardized for FSH in vivo bioactivity in terms of the First
International Reference Preparation for human menopausal gonadotropins (code
70/45), issued by the World Health Organization Expert Committee on Biological
Standardization (1982). Under current storage conditions, Follistim®
AQ Cartridge may contain up to 11% of oxidized follitropin beta.
In clinical trials with Follistim® (follitropin beta for injection),
serum antibodies to FSH or anti-CHO cell derived proteins were not detected
in any of the treated patients after exposure to Follistim® for up
to three cycles.
Therapeutic Class: Infertility
1 As determined by the Ph. Eur. test for FSH in vivo bioactivity
and on the basis of the molar extinction coefficient at 277 nm (ε s:mg-1cm-1)
= 1.066.Last reviewed on RxList: 2/27/2009




Follistim AQ Cartridge Drug Description
Follistim® AQ Cartridge
(follitropin beta) Injection
FOR SUBCUTANEOUS USE ONLY
DRUG DESCRIPTION



What are the possible side effects of follicle stimulating hormone (Follistim, Follistim AQ, Gonal-F, Gonal-f RFF, Gonal-f RFF Pen)?

Stop using follicle stimulating hormone and seek emergency medical attention or notify your doctor immediately if you experience any of the following serious side effects:

an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
pain, warmth, redness, numbness, or tingling in an arm or leg (which may indicate a blood clot);
confusion, severe...
Read All Potential Side Effects for Follistim AQ Cartridge »




Follistim® AQ Cartridge (follitropin beta injection) contains human follicle-stimulating
hormone (hFSH), a glycoprotein hormone which is manufactured by recombinant
DNA (rDNA) technology. The active drug substance, follitropin beta, has a dimeric
structure containing two glycoprotein subunits (alpha and beta). Both the 92
amino acid alpha-chain and the 111 amino acid beta-chain have complex heterogeneous
structures arising from two N-linked oligosaccharide chains. Follitropin beta
is synthesized in a Chinese hamster ovary (CHO) cell line that has been transfected
with a plasmid containing the two subunit DNA sequences encoding for hFSH. The
purification process results in a highly purified preparation with a consistent
hFSH isoform profile and high specific activity.1 The biological
activity is determined by measuring the increase in ovary weight in female rats.
The intrinsic luteinizing hormone (LH) activity in follitropin beta is less
than 1 IU per 40,000 IU FSH. The compound is considered to contain no LH activity.

The amino acid sequence and tertiary structure of follitropin beta are indistinguishable
from that of human follicle-stimulating hormone (hFSH) of urinary source. Also,
based on available data derived from physiochemical tests and bioassay, follitropin
beta and follitropin alfa, another recombinant follicle-stimulating hormone
product, are indistinguishable.
Follistim® AQ Cartridge is a ready-for-use, prefilled with solution, disposable
cartridge containing either 175 IU of follitropin beta in 0.210 mL (833 IU/mL),
350 IU in 0.420 mL (833 IU/mL), 650 IU in 0.780 mL (833 IU/mL) or 975 IU in
1.170 mL (833 IU/mL) of aqueous solution for multiple dose use, with a maximal
deliverable dose of either 150 IU, 300 IU, 600 IU or 900 IU, respectively.
Inactive ingredients in the cartridges include: benzyl alcohol, NF 10 mg/mL;
L-methionine, USP 0.5 mg/mL; polysorbate 20, NF 0.2 mg/mL; sodium citrate (dihydrate),
USP 14.7 mg/mL; sucrose, NF 50 mg/mL; and water for injection, USP. Hydrochloric
acid, NF and/or sodium hydroxide, NF are used to adjust the pH to 7.
Follistim® AQ Cartridge is for use only with the Follistim Pen®, which
features an adjustable dosing system for administering the drug in a microvolume
of solution. The Follistim Pen®with Follistim® AQ Cartridge is intended
for SUBCUTANEOUS USE ONLY. The recombinant protein in Follistim® AQ Cartridge
has been standardized for FSH in vivo bioactivity in terms of the First
International Reference Preparation for human menopausal gonadotropins (code
70/45), issued by the World Health Organization Expert Committee on Biological
Standardization (1982). Under current storage conditions, Follistim®
AQ Cartridge may contain up to 11% of oxidized follitropin beta.
In clinical trials with Follistim® (follitropin beta for injection),
serum antibodies to FSH or anti-CHO cell derived proteins were not detected
in any of the treated patients after exposure to Follistim® for up
to three cycles.
Therapeutic Class: Infertility
1 As determined by the Ph. Eur. test for FSH in vivo bioactivity
and on the basis of the molar extinction coefficient at 277 nm (ε s:mg-1cm-1)
= 1.066.Last reviewed on RxList: 2/27/2009




Follistim AQ Cartridge Drug Description
Follistim® AQ Cartridge
(follitropin beta) Injection
FOR SUBCUTANEOUS USE ONLY
DRUG DESCRIPTION



What are the possible side effects of follicle stimulating hormone (Follistim, Follistim AQ, Gonal-F, Gonal-f RFF, Gonal-f RFF Pen)?

Stop using follicle stimulating hormone and seek emergency medical attention or notify your doctor immediately if you experience any of the following serious side effects:

an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
pain, warmth, redness, numbness, or tingling in an arm or leg (which may indicate a blood clot);
confusion, severe...
Read All Potential Side Effects for Follistim AQ Cartridge »




Follistim® AQ Cartridge (follitropin beta injection) contains human follicle-stimulating
hormone (hFSH), a glycoprotein hormone which is manufactured by recombinant
DNA (rDNA) technology. The active drug substance, follitropin beta, has a dimeric
structure containing two glycoprotein subunits (alpha and beta). Both the 92
amino acid alpha-chain and the 111 amino acid beta-chain have complex heterogeneous
structures arising from two N-linked oligosaccharide chains. Follitropin beta
is synthesized in a Chinese hamster ovary (CHO) cell line that has been transfected
with a plasmid containing the two subunit DNA sequences encoding for hFSH. The
purification process results in a highly purified preparation with a consistent
hFSH isoform profile and high specific activity.1 The biological
activity is determined by measuring the increase in ovary weight in female rats.
The intrinsic luteinizing hormone (LH) activity in follitropin beta is less
than 1 IU per 40,000 IU FSH. The compound is considered to contain no LH activity.

The amino acid sequence and tertiary structure of follitropin beta are indistinguishable
from that of human follicle-stimulating hormone (hFSH) of urinary source. Also,
based on available data derived from physiochemical tests and bioassay, follitropin
beta and follitropin alfa, another recombinant follicle-stimulating hormone
product, are indistinguishable.
Follistim® AQ Cartridge is a ready-for-use, prefilled with solution, disposable
cartridge containing either 175 IU of follitropin beta in 0.210 mL (833 IU/mL),
350 IU in 0.420 mL (833 IU/mL), 650 IU in 0.780 mL (833 IU/mL) or 975 IU in
1.170 mL (833 IU/mL) of aqueous solution for multiple dose use, with a maximal
deliverable dose of either 150 IU, 300 IU, 600 IU or 900 IU, respectively.
Inactive ingredients in the cartridges include: benzyl alcohol, NF 10 mg/mL;
L-methionine, USP 0.5 mg/mL; polysorbate 20, NF 0.2 mg/mL; sodium citrate (dihydrate),
USP 14.7 mg/mL; sucrose, NF 50 mg/mL; and water for injection, USP. Hydrochloric
acid, NF and/or sodium hydroxide, NF are used to adjust the pH to 7.
Follistim® AQ Cartridge is for use only with the Follistim Pen®, which
features an adjustable dosing system for administering the drug in a microvolume
of solution. The Follistim Pen®with Follistim® AQ Cartridge is intended
for SUBCUTANEOUS USE ONLY. The recombinant protein in Follistim® AQ Cartridge
has been standardized for FSH in vivo bioactivity in terms of the First
International Reference Preparation for human menopausal gonadotropins (code
70/45), issued by the World Health Organization Expert Committee on Biological
Standardization (1982). Under current storage conditions, Follistim®
AQ Cartridge may contain up to 11% of oxidized follitropin beta.
In clinical trials with Follistim® (follitropin beta for injection),
serum antibodies to FSH or anti-CHO cell derived proteins were not detected
in any of the treated patients after exposure to Follistim® for up
to three cycles.
Therapeutic Class: Infertility
1 As determined by the Ph. Eur. test for FSH in vivo bioactivity
and on the basis of the molar extinction coefficient at 277 nm (ε s:mg-1cm-1)
= 1.066.Last reviewed on RxList: 2/27/2009





Other reviews about Follitropin Beta Injection on wordpress

Follistim Pen Injections
  by babystuess
I've now had all 3 of my Follistim shots.  Alex & I decided that we would administer the shots at 6:30 pm each night.  On Friday night, we […]


Merck - Schering-Plough
  by El Horror
About - Schering-Plough = Merger of Schering Corporation and Plough Inc. in 1971. - 2009: Merger of Merck & Co. Inc. (68%) and Schering-Plough (32%). 41.1 billion dollar deal by […]



Other reviews about Follitropin Beta Injection on web:

Consumer information about the medication FOLLITROPIN BETA - INJECTION (Follistim), includes side effects, drug interactions, recommended dosages, and storage information. FOLLITROPIN BETA - INJECTION (Follistim) side effects, medical ...


Follitropin Beta Solution for injection To return to the main entry click here . What is this medicine? FOLLITROPIN BETA (fol li TROE pin BAY Follitropin Beta Solution for injection: Information from Answers.com


Follitropin Beta, Injection foh-li-TROH-pin BAY-ta What are other names for this medicine? Type of medicine: gonadotropin; infertility therapy; ovulation stimulator CRS Topic


Follistim® AQ Cartridge (follitropin beta injection)... ... How Follistim® AQ Cartridge Works; Recombinant DNA Technology; Frequently Asked Questions 00 Follistim AQ Cartridge


Learn about the prescription medication Follistim AQ Cartridge (Follitropin Beta Injection), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient ... Follistim AQ Cartridge (Follitropin Beta Injection) Drug ...


Follitropin Beta (fol-i-TROE-pin BAY-ta) Treats infertility in women. This medicine is a hormone. Follitropin beta (Injection)


You should not use this medicine if you have had an allergic reaction to follitropin beta ... Make sure you understand all instructions before giving yourself an injection. St. Luke's Sugar Land Hospital - Your Health Topics


You should not use this medicine if you have had an allergic reaction to follitropin beta ... Make sure you understand all instructions before giving yourself an injection. Kelsey-Seybold Clinic - Welcome


follitropin beta-injection glossary includes a list of follitropin beta-injection related medical definitions and related links on MedicineNet.com follitropin beta-injection Glossary of Terms with Definitions on ...


Follistim® AQ Vial (follitropin beta injection) is a medicine that contains the follicle-stimulating hormone (FSH). FSH helps (stimulate) healthy ovar... Frequently Asked Questions





Featured Reviews

Reviews Clofazimine

Lamprene Drug Description Lamprene® (clofazimine) Soft Gelatin Capsules DRUG DESCRIPTION Lamprene, clofazimine, is an antileprosy agent available as soft gelatin capsules for oral administration. Each capsule contains 50 mg of micronized...
Read More  |  Review This
Reviews Gadobenate Dimeglumine Injection

Multihance Drug Description MultiHance (gadobenate dimeglumine) Injection WARNING: NEPHROGENIC SYSTEMIC FIBROSIS NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF)...
Read More  |  Review This
Reviews Tolterodine Tartrate

Detrol Drug Description Detrol® (tolterodine tartrate) Tablets DRUG DESCRIPTION What are the possible side effects of tolterodine (Detrol, Detrol LA)? Get emergency medical help if you have any of these signs of an allergic...
Read More  |  Review This
Reviews Folacin, Cyanocobalamin & Pyridoxine

Foltx Drug Description FOLTX ® Tablets A medical food for the dietary management of hyperhomocysteinemia. DRUG DESCRIPTION Each round coated beige colored tablet contains: Active Ingredients: Folacin (Folic Acid) ...
Read More  |  Review This
Reviews Pentazocine and Aspirin

Talwin Compound Drug Description DRUG DESCRIPTION TALWIN Compound is a combination of pentazocine hydrochloride, USP, equivalent to 12.5 mg base and aspirin, USP, 325 mg. Pentazocine is a member of the benzazocine series (also known...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....